AcelRx Pharmaceuticals Inc  

(Public, NASDAQ:ACRX)   Watch this stock  
Find more results for ACRX
10.83
+0.61 (5.97%)
Jul 25 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 10.52 - 11.38
52 week 6.04 - 13.64
Open 10.98
Vol / Avg. 4.00M/914,344.00
Mkt cap 469.68M
P/E     -
Div/yield     -
EPS -0.54
Shares 43.37M
Beta 1.65
Inst. own 90%
Aug 19, 2014
AcelRx Pharmaceuticals, Inc. at Guggenheim Securities, LLC One on One Day Add to calendar
Aug 13, 2014
AcelRx Pharmaceuticals, Inc. at Canaccord Genuity Growth Conference - 2:30PM EDT - Add to calendar
Aug 11, 2014
Q2 2014 AcelRx Pharmaceuticals, Inc. Earnings Release (Estimated) Add to calendar
Jul 24, 2014
AcelRx Pharmaceuticals Inc Annual Shareholders Meeting
Jun 26, 2014
AcelRx Pharmaceuticals Inc at Biotechnology Industry Organization (BIO) International Convention
Jun 25, 2014
AcelRx Pharmaceuticals, Inc. at JMP Securities Healthcare Conference
Jun 24, 2014
AcelRx Pharmaceuticals Inc at ROTH Healthcare Corporate Access Day
Jun 3, 2014
AcelRx Pharmaceuticals, Inc. at Jefferies Global Healthcare Conference - Webcast
May 20, 2014
AcelRx Pharmaceuticals, Inc. at UBS Global Healthcare Conference - Webcast
May 8, 2014
Q1 2014 AcelRx Pharmaceuticals, Inc. Earnings Conference Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin -10137.89% -79.40%
Operating margin -8990.53% -22.60%
EBITD margin - -20.59%
Return on average assets -36.71% -26.84%
Return on average equity -55.90% -43.78%
Employees 27 -
CDP Score - -

Address

351 Galveston Drive
REDWOOD CITY, CA 94063
United States - Map
+1-650-2163500 (Phone)
+1-650-2166500 (Fax)

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

AcelRx Pharmaceuticals, Inc. is a United States-based Pharmaceutical Company, which develops and commercializes therapies for the treatment of pain. The Company's products include ARX-01 Sufentanil NanoTab PCA System, to solve the problems associated with post-operative intravenous patient-controlled analgesia (IV PCA); ARX-02 Sufentanil NanoTab BTP Management System is a treatment option for cancer patients who suffer from breakthrough pain (BTP). ARX-03 Sufentanil/Triazolam NanoTab, provides non-invasive mild sedation, anxiety reduction and pain relief; and ARX-04 Sufentanil Acute Pain NanoTab, is a sublingual sufentanil product candidate designed to provide a non-invasive, fast-onset treatment of patients with moderate-to-severe acute pain, both on the battlefield and in civilian settings of trauma or injury.

Officers and directors

Adrian Adams Independent Chairman of the Board
Age: 63
Bio & Compensation  - Reuters
Richard A. King President, Chief Executive Officer, Director
Age: 49
Bio & Compensation  - Reuters
Timothy E. Morris Chief Financial Officer, Principal Accounting Officer
Age: 53
Bio & Compensation  - Reuters
Pamela P. Palmer M.D. Ph.D. Chief Medical Officer, Director
Age: 51
Bio & Compensation  - Reuters
Badri N. Dasu Chief Engineering Officer
Age: 50
Bio & Compensation  - Reuters
Lawrence G. Hamel Chief Development Officer
Age: 62
Bio & Compensation  - Reuters
Richard F. Afable M.D. Director
Age: 60
Bio & Compensation  - Reuters
Mark G. Edwards Independent Director
Age: 56
Bio & Compensation  - Reuters
Stephen J. Hoffman M.D. Ph.D. Independent Director
Age: 60
Bio & Compensation  - Reuters
Howard B. Rosen Independent Director
Age: 55
Bio & Compensation  - Reuters